Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies

被引：1

作者：

Jakubowiak, Andrzej ^{[1
]}

Jasielec, Jagoda ^{[2
]}

Rosenbaum, Cara ^{[3
]}

Orlowski, Robert Z. ^{[4
]}

Cohen, Adam ^{[5
]}

Bensinger, William I. ^{[6
]}

Anderson, Aparna ^{[7
]}

Dossett, Tommy ^{[7
]}

Iskander, Karim ^{[8
]}

Mezzi, Khalid ^{[8
]}

Welliver, Timothy ^{[8
]}

Yusuf, Akeem ^{[8
]}

Durie, Brian ^{[9
]}

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[6] Swedish Canc Inst, Seattle, WA USA

[7] Stat Collaborat Inc, Washington, DC USA

[8] Amgen Inc, Thousand Oaks, CA 91320 USA

[9] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期

关键词：

carfilzomib; Pomalidomide; relapsed/refractory multiple myeloma;

D O I：

10.1016/j.clml.2019.09.050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OAB-049

引用

页码：E34 / E34

页数：1

共 50 条

[41] Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Huixing Zhou
Yafei Wang
Jiao Chen
Aili He
Jie Jin
Quanyi Lu
Ying Zhao
Junjun Li
Ming Hou
Liping Su
Xun Lai
Wei Wang
Lihong Liu
Yanping Ma
Da Gao
Wenhong Lai
Xin Zhou
Hongmei Jing
Jinqiao Zhang
Wei Yang
Xuehong Ran
Congmeng Lin
Jianping Hao
Taiwu Xiao
Zhenqian Huang
Zhigang Zhu
Qing Wang
Baijun Fang
Binghua Wang
Yanping Song
Zhen Cai
Bo Liu
Yanan Zhu
Xinai Yang
Xiaoyan Kang
Juan Li
Wenming Chen
Annals of Hematology, 2024, 103 : 855 - 868
[42] Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Zhou, Huixing
Wang, Yafei
Chen, Jiao
He, Aili
Jin, Jie
Lu, Quanyi
Zhao, Ying
Li, Junjun
Hou, Ming
Su, Liping
Lai, Xun
Wang, Wei
Liu, Lihong
Ma, Yanping
Gao, Da
Lai, Wenhong
Zhou, Xin
Jing, Hongmei
Zhang, Jinqiao
Yang, Wei
Ran, Xuehong
Lin, Congmeng
Hao, Jianping
Xiao, Taiwu
Huang, Zhenqian
Zhu, Zhigang
Wang, Qing
Fang, Baijun
Wang, Binghua
Song, Yanping
Cai, Zhen
Liu, Bo
Zhu, Yanan
Yang, Xinai
Kang, Xiaoyan
Li, Juan
Chen, Wenming
ANNALS OF HEMATOLOGY, 2024, 103 (03) : 855 - 868
[43] Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
Dimopoulos, M. A.
Sonneveld, P.
Siegel, D.
Palumbo, A.
San-Miguel, J.
ANNALS OF ONCOLOGY, 2015, 26 (11) : 2247 - 2256
[44] EFFICACY AND SAFETY OF BORTEZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sanchez, R. Garcia
Saldana, R.
Caparros, I.
Gallardo, A.
Garcia-Delgado, R.
Rosell, A.
Campos, A.
de Llano, M. P. Queipo
Perez, I.
Moreno, M. J.
Del Castillo, S.
De la Torre, S.
Ramirez, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 500 - 500
[45] Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
Jagannath, Sundar
Berdeja, Jesus
Rifkin, Robert
Cole, Craig
Thompson, Michael A.
Ricafort, Rosanna J.
Scofield, Amanda
Mohamed, Hesham
Sy, Oumar
Vij, Ravi
Bensinger, William
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E127 - E127
[46] Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
Jagannath, Sundar
Berdeja, Jesus
Rifkin, Robert
Cole, Craig
Thompson, Michael A.
Ricafort, Rosanna J.
Scofield, Amanda
Mohamed, Hesham
Sy, Oumar
Vij, Ravi
Bensinger, William
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S331
[47] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
Badros, Ashraf Z.
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander M.
Rapoport, Aaron P.
Kocoglu, Mehmet H.
Lederer, Emily
Philip, Sunita
Lesho, Patricia
Johnson, Ashlee
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
BLOOD, 2016, 128 (22)
[48] Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma
Mark, Tomer M.
Boyer, Angelique
Rossi, Adriana C.
Kwon, Dennis
Pearse, Roger N.
Zafar, Faiza
Pekle, Karen
Tegnestam, Linda
Jayabalan, David
Ely, Scott A.
Coleman, Morton
Chen-Kiang, Selina
Niesvizky, Ruben
BLOOD, 2013, 122 (21)
[49] Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable safety profile
Richardson, Paul
Htut, Myo
Scott, Emma
Prada, Claudia Paba
Gupta, Ira
HAEMATOLOGICA, 2025, 110 (02) : 488 - 492
[50] ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
Mark, Tomer M.
Boyer, Angelique
Rossi, Adriana C.
Shah, Manan
Pearse, Roger N.
Zafar, Faiza
Pekle, Karen
Tegnestam, Linda
Sacris, Erlinda A.
Greenberg, June
Speaker, Stephanie
Jayabalan, David
Ely, Scott A.
Coleman, Morton
Chen-Kiang, Selina
Niesvizky, Ruben
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →